A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Ohio State University Comprehensive Cancer Center
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Revolution Medicines, Inc.
Centre hospitalier de l'Université de Montréal (CHUM)
GlaxoSmithKline
Accent Therapeutics
A2 Biotherapeutics Inc.
National Institutes of Health Clinical Center (CC)
Revolution Medicines, Inc.
University of Colorado, Denver
GlaxoSmithKline